DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Clinical Assessment Of Association Pharmacokinetics Atorvastatin + Lorsatana + Hydrochlorothiazide Produced By Lab Hypermarcas S/A. In Healthy Subjects

Information source: L.A.L Clinica Pesquisa e Desenvolvimento Ltda.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy Subjects

Intervention: Atorvastatin (Drug); Hydrochlorothiazide + Losartan (Drug); Hydrochlorothiazide + Losartan + Atorvastatin (Drug)

Phase: Phase 1

Status: Not yet recruiting

Sponsored by: L.A.L Clinica Pesquisa e Desenvolvimento Ltda.

Overall contact:
Alexandre Frederico, physician, Phone: 55 19 38716399, Email: alexandre@lalclinica.com.br


The objective of this clinical study, randomized, crossover is to evaluate the pharmacokinetic profile of the polypill (atorvastatin + lorsatana + hydrochlorothiazide)

Laboratory Hypermarcas S / A, in relation to drugs Citalor (atovastatina - Pfizer) and

Hyzaar (losartan + hydrochlorothiazide - Merck Sharp & Dohme) by comparing the serum

concentration of analytes unchanged (AT, LS and HCTZ) in healthy subjects.

Clinical Details

Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: The primary pharmacokinetic parameters for the exercise of comparability will be unchanged dosages of analytes (AT, LS and HCTZ), assessed by AUC, Tmax, Cmax and T1 / 2.

Secondary outcome: Pharmacokinetic parameters are side dosages of active metabolites O-HAT and E-3174, measured by AUC, Tmax, Cmax and T1 / 2.

Detailed description: The pharmacokinetic profile of the drug will also be assessed by comparing the serum concentration of active metabolites following:

- O-hydroxy atorvastatin (2-Hydroxy atorvastatin, O-HAT): metabolite of AT

- carboxylic acid (E-3174, LS-CA): active metabolite of LS


Minimum age: 18 Years. Maximum age: 55 Years. Gender(s): Both.


Inclusion Criteria: 1. Confirm voluntary participation and agree to all the purposes of the study by signing and dating the IC in two ways; 2. Age between 18 and 55 years, regardless of sex, clinically healthy and present laboratory parameters within normal limits; 3. BMI ≥ 18. 5 and ≤ 30. Exclusion Criteria: 1. Participation in clinical trials in the 12 months preceding the survey; 2. History of hypersensitivity reactions to atorvastatin, losartan hydrochlorothiazide and / or any other ingredients of medicines; 3. Alterations in clinical and laboratory criteria that interfere Principal Investigator on the study results; 4. Presence of pulmonary diseases, cardiovascular, neurological, endocrine, gastrointestinal, genitourinary or other systems; 5. Acute illness during the 07 days preceding the start of the study; 6. Chronic disease that determine drug delivery, such as hypertension, diabetes or any other that requires continuous use of any medicine, including use of vitamins, mineral supplements and OTCs (over-the-counter); 7. Having made regular use of medication in the last 02 weeks before the onset of the study. The use of any medication that does not interfere with the physician's judgment on the pharmacokinetics of the drug under study, will not be considered as an exclusion criterion. 8. Use of medications that interact with any medications association; 9. History of or current use for at least 12 months of tobacco; 10. Current or previous history (under 12 months) of illicit drug use; 11. At the discretion of the Principal Investigator of the study.

Locations and Contacts

Alexandre Frederico, physician, Phone: 55 19 38716399, Email: alexandre@lalclinica.com.br

LAL Clínica Pesquisa e Desenvolvimento Ltda, Valinhos, São Paulo, Brazil; Not yet recruiting
Alexandre Frederico, physician, Phone: 55 19 38716399, Email: alexandre@lalclinica.com.br
Additional Information

Starting date: February 2013
Last updated: September 24, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017